GCC Pharmaceutical Market Opportunity Insight 2025

GCC Pharmaceutical Market Opportunity Insight 2025

No. of Pages: 350
Publish Date: January-2020
Category: Pharmaceutical and Healthcare

Electronic Access - Single User License

$3600

CD-ROM Mail Delivery

$4200

Hard Copy Mail Delivery

$5100

Electronic Access - Multi-User License

$6600

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

"GCC Pharmaceutical Market Opportunity Insight 2025" Report Highlights:

GCC Pharmaceutical Market Opportunity: > US$ 20 Billion
Patented and OTC Pharmaceutical Market Size: 75% of Total Market
Share of Imported Drugs In GCC Pharmaceutical Market: > 80%
Saudi Arabia Dominates GCC Pharmaceutical Market: 50% Market Share
GCC Pharmaceutical Clinical Trials Insight: > 700 Drugs

The research report "GCC Pharmaceutical Market Opportunity Insight 2025" provides an in-depth analysis about the current market dynamics that includes drivers, trends and opportunities which are subjected to have an influence on the market of the pharmaceutical products in the GCC region. Various important factors that are supported by the governments of the GCC countries for various agents commercialized in the region are also provided in a segmented way in the research report. The impact of the regulatory scenario that is prevailing upon the major key players of the region is also discussed in the report.

The research conducted on the respective subject highlights the distribution of the market based on the profiles of the companies and their respective efforts in increasing the production and value of the product exponentially. The anticipation of the pharmaceutical market in the GCC region is believed to be the result of the factors that are hindering the people of GCC region such as rapid change in the dynamics of the population, geriatric population and most importantly increasing prevalence of lifestyle associated diseases such as diabetes, obesity, cardiovascular diseases.

"GCC Market Offers Unexplored and Exponential Growth Opportunities For Global Pharmaceutical Companies As Imports Accounts For More Than 80% Regional Pharmaceutical Products Sales."

With the increasing disorders associated with lifestyle of the gulf population, the government policies along with regulatory framework became more poised towards the promoting the growth of the pharmaceutical market in the region. Factors like these are most prominent in developing a huge difference and marking an exponential growth rate in the market size of GCC pharmaceutical market in the coming years. Over the years, the branded drugs market has been dominating the market of GCC pharmaceuticals and most pre-dominantly among all the countries included in GCC, Saudi Arabia compiled of maximum share of the market.

Saudi Arabia, among the other gulf countries is a region with major dominant traits. Economic viability, changing legislative and framework are the main driving forces for the establishment of such high-valued pharmaceutical market in the gulf. Slowly and steadily, new frontiers of the pharmaceutical market are making their way to the gulf and imposing their need for the development of generic drug over the market of branded drugs. The alternative form of the drugs available in the market will end up in the up-regulation of the overall market trends by many folds.

“The Growing Demand Of The Generic And Branded Pharmaceuticals That Is Driven By The Various Government Policies And Cost Effective Facilities, Is Considered As A Significant Opportunity For The Drug Manufacturers In The GCC.”

The sales record achieved from the gulf countries establishes Saudi Arabia as an emerging ground for the pharmaceutical market, with UAE and others as a prominent region for expanding the market. The Imported drug market established in the region constitutes a major portion of the GCC pharmaceutical market. More than 80% of the drug utilized in the gulf countries is imported from the major players established in the Western countries. The percent mentioned indicates a huge demand of the drugs either imported or manufactured in the local region. Both aspects of the pharmaceutical market suggest a high demand of the pharmaceutical drugs in the market and eventually a prevailing commercial success.

Introduction to Gulf Cooperation Council (GCC) Pharmaceutical Market

1.1 Overview

1.2 GCC Pharmaceutical Market Analysis

GCC Pharmaceutical Market by Indication - Prevalence and Statistics

2.1 Cancer

2.1.1 Overview

2.1.2 Prevalence by Cancer Type and Gender

2.1.3 Cancer Prevalence and Statistics by GCC Countries

2.2 Diabetes

2.3 HIV/AIDS

2.4 Cardiovascular Diseases

2.4.1 Coronary Heart Disease

2.4.2 Hypertension

2.4.3 Stroke

2.5 Obesity

2.6 Respiratory Disorders

2.6.1 Asthma

2.6.2 Tuberculosis

2.6.3 Influenza and Pneumonia

2.6.4 Other Respiratory Diseases - COPD and Cystic Fibrosis

2.7 Alzheimer's Disease/Dementia

GCC - Regulatory Aspects of Pharmaceuticals

3.1 Gulf Central Committee for Drug Registrations (GCC-DR)

3.2 Regulatory Review Process

3.3 Centralized Registration

3.4 Decentralized Drug Registration Regulation

3.4.1 Saudi Arabia

3.4.2 Kuwait

3.4.3 UAE

3.4.4 Bahrain

3.4.5 Qatar

3.4.6 Oman

3.5 Gulf Joint Procurement Program

GCC - Pharmaceutical Pricing and Reimbursement Policies

4.1 Pricing Policies

4.1.1 In-Patent Pharmaceuticals

4.1.2 Off-Patent and Generic Pharmaceuticals

4.1.3 Locally and Multinational Manufactured Pharmaceuticals

4.2 Procurement and Reimbursement Policies

4.2.1 In-Patent Pharmaceuticals

4.2.2 Off-Patent, Generics and Biosimilars

GCC Pharmaceutical Market by Product

5.1Generics Pharmaceuticals

5.2 Patented and OTC Pharmaceuticals

5.3 Biosimilars

Saudi Arabia Pharmaceutical Market Analysis

6.1 Overview

6.2 Saudi Arabia Pharmaceutical Market by Products

6.3 Saudi Arabia Pharmaceutical Market by Companies

6.4 Saudi Arabia Pharmaceutical Market by Type

UAE Pharmaceutical Market Analysis

7.1 Overview

7.2 UAE Pharmaceuticals Market by Product

7.3 UAE Pharmaceutical Market by Companies

7.4 UAE Pharmaceutical Market by Type

Kuwait Pharmaceutical Market Analysis

8.1 Overview

8.2 Kuwait Pharmaceutical Market by Therapeutic Indication and Products

8.3 Kuwait Pharmaceutical Market by Companies

8.4 Kuwait Pharmaceutical Market by Type

Bahrain Pharmaceutical Market Analysis

9.1 Overview

9.2 Bahrain Pharmaceutical Market by Products

9.3 Bahrain Pharmaceutical market by Companies

9.4 Bahrain Pharmaceutical Market by Product Type

Qatar Pharmaceutical Market Analysis

10.1 Overview

10.2 Qatar Pharmaceutical Market by Type

Oman Pharmaceutical Market Analysis

11.1 Overview

11.2 Oman Pharmaceutical Market by Product Type

GCC Pharmaceutical Market - International Trade

12.1 Import Market

12.2 Pharmaceutical Export Market

GCC Pharmaceutical Market - Clinical Insight

13.1 Overview

13.2 Clinical Trials by Indication

13.2.1 Cancer

13.2.2 Diabetes

13.2.3 CVS Disorders

13.2.4 Respiratory Disorders

13.3 Clinical Insight by GCC Countries

13.3.1 Saudi Arabia

13.3.2 United Arab Emirates

13.3.3 Kuwait

13.3.4 Bahrain

13.3.5 Qatar

13.3.6 Oman

GCC Pharmaceutical Market Drivers

Challenges for GCC Pharmaceutical Market

GCC Pharmaceutical Market Future Outlook - Trends and Opportunities

Competitive Landscape

17.1 Local Pharmaceutical Companies

17.1.1 Julphur Pharmaceuticals

17.1.2 SPIMACO Addwaeih

17.1.3 Qatar Life Pharma

17.1.4 Al Mojil Drug Company

17.1.5 Kuwait Saudi Pharmaceutical Company

17.1.6 YIACO Medical Company

17.1.7 Qatar Pharma

17.1.8 Saja Pharmaceuticals

17.1.9 Oman Pharmaceuticals

17.1.10 Taiba Pharmaceuticals

17.1.11 Gulf Biotech

17.1.12 Bahrain Pharma

17.1.13 Neopharma

17.1.14 Planet Pharmacies

17.1.15 Aljazeera Pharmaceutical Industries

17.1.16 Dallah Pharma

17.1.17 Tabuk Pharmaceuticals

17.1.18 CAD Middle-East Pharmaceutical Company

17.1.19 ACDIMA

17.1.20 AL-Mufid Pharmaceuticals

17.2 Multinational Companies

17.2.1 Novartis

17.2.2 Amgen

17.2.3 Eli - Lilly

17.2.4 Merck

17.2.5 Pfizer

17.2.6 GlaxoSmithKline plc

17.2.7 Roche

17.2.8 Takeda Pharmaceuticals

17.2.9 Teva Pharmaceuticals

17.2.10 AstraZeneca plc

17.2.11 Genentech

17.2.12 Sanofi

Figure 1-1: Pharmaceutical Market Size - Global vs. GCC (US$ Billion), 2018

Figure 1-2: GCC vs. Rest of World - Pharmaceutical Market Size (%), 2018

Figure 1-3: GCC - Population Statistics (Million), 2019

Figure 1-4: GCC - Population by Countries (%), 2019

Figure 1-5: GCC - Healthcare Expenditure by Countries (US$ Billion), 2018

Figure 1-6: GCC - Healthcare Expenditure by Countries (%), 2018

Figure 1-7: GCC - Pharmaceutical Market Size (US$ Billion), 2016 and 2018

Figure 1-8: GCC Pharmaceutical Market Size (US$ Billion), 2018 - 2025

Figure 1-9: MEA vs. GCC - Pharmaceutical Market Size (US$ Billion), 2018

Figure 1-10: GCC vs. Rest of MEA - Pharmaceutical Market Size (%), 2018

Figure 1-11: GCC - Pharmaceutical Market Size by Countries (US$ Billion), 2018

Figure 1-12: Pharmaceutical Market Size of Various GCC Countries (%), 2018

Figure 2-1: GCC - Number of Newly Diagnosed Cancer Cases and Deaths, 2018

Figure 2-2: GCC - Number of New Cancer Cases by Countries, 2018

Figure 2-3: GCC - New Cancer Cases by Countries (%), 2018

Figure 2-4: GCC - Number of Cancer Related Deaths by Countries, 2018

Figure 2-5: GCC - New Cancer Cases by Countries (%), 2018

Figure 2-6: GCC - Number of Newly Diagnosed Cancer Cases, 2018 and 2030

Figure 2-7: GCC - Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018

Figure 2-8: GCC - Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018

Figure 2-9: GCC Pharmaceutical Market Size - Total vs. Cancer Drugs (US$ Billion), 2018

Figure 2-10: GCC - Cancer Drug Market Size by Countries (%), 2018

Figure 2-11: GCC - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-12: GCC - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-13: GCC - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-14: GCC - Cancer Cases by Gender (%), 2018

Figure 2-15: GCC - Cancer Deaths by Gender (%), 2018

Figure 2-16: GCC - Age Standardized Cancer Incidence and Mortality Rate (per 100,000 People), 2018

Figure 2-17: Saudi Arabia - Number of Cancer Cases and Deaths, 2018

Figure 2-18: Saudi Arabia - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-19: Saudi Arabia - New Diagnosed Cancer Cases by Gender (%), 2018

Figure 2-20: Saudi Arabia - Cancer Related Deaths by Gender (%), 2018

Figure 2-21: Saudi Arabia - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-22: UAE - Number of Cancer Cases and Deaths, 2018

Figure 2-23: UAE - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-24: UAE - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-25: UAE - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-26: Kuwait - Number of Cancer Cases and Deaths, 2018

Figure 2-27: Kuwait - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-28: Kuwait - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-29: Kuwait - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-30: Bahrain - Number of Cancer Cases and Deaths, 2018

Figure 2-31: Bahrain - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-32: Bahrain - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-33: Bahrain - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-34: Qatar - Number of Cancer Cases and Deaths, 2018

Figure 2-35: Qatar - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-36: Qatar - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-37: Qatar - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-38: Oman - Number of Cancer Cases and Deaths, 2018

Figure 2-39: Oman - Number of Cancer Cases and Deaths by Gender, 2018

Figure 2-40: Oman - New Diagnosed Cases by Cancer Type (%), 2018

Figure 2-41: Oman - Number of New Diagnosed Cases by Cancer Type, 2018

Figure 2-42: GCC - Total Adult Population and Diabetic Population (Million), 2017

Figure 2-43: GCC - Total Adult Population and Diabetic Population (%), 2017

Figure 2-44: GCC - Diabetic Population by Countries (Million), 2017

Figure 2-45: GCC - Diabetic Population by Countries (%), 2017

Figure 2-46: GCC - Diabetes Related Deaths by Countries, 2017

Figure 2-47: GCC - Diabetes Related Deaths by Countries (%), 2017

Figure 2-48: GCC - Diabetes Prevalence Rate by Countries (%), 2017

Figure 2-49: GCC - Age Standardized Diabetes Death Rate by Countries (Per 100,000 People), 2017

Figure 2-50: GCC - Diabetic Population (Billion), 2017, 2018 and 2045

Figure 2-51: Saudi Arabia - Total HIV Cases and Newly Diagnosed HIV Cases, 2017

Figure 2-52: Saudi Arabia - New Diagnosed HIV Cases, 2013 - 2017

Figure 2-53: Saudi Arabia - New Diagnosed HIV Cases by Gender, 2017

Figure 2-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017

Figure 2-55: Saudi Arabia - Total HIV Cases by Gender, 2017

Figure 2-56: Saudi Arabia - Total HIV Cases by Gender, 2017

Figure 2-57: Saudi Arabia - Cumulative HIV Related Deaths by Gender, 2017

Figure 2-58: Saudi Arabia - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017

Figure 2-59: UAE - Cumulative Number of HIV Patients, 2012, 2014 and 2016

Figure 2-60: UAE - Number of New HIV Cases and Deaths, 2016

Figure 2-61: UAE - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 and 2018

Figure 2-62: UAE - Cumulative Number of HIV Patients, 2014 - 2018

Figure 2-63: Bahrain - HIV Associated New Cases and Deaths, 2016

Figure 2-64: Bahrain - Patients Receiving Antiretroviral Therapy (%), 2012, 2014 and 2016

Figure 2-65: Qatar - Cumulative Number of HIV Cases and Patients on Antiretroviral Therapy, 1984 - 2014

Figure 2-66: Qatar - HIV Patients on Anti-Retroviral Therapy, 1984 - 2014

Figure 2-67: Oman - Cumulative HIV Cases, 2014, 2016 and 2018

Figure 2-68: Oman - Cumulative HIV Cases by Gender, 2018

Figure 2-69: Oman - Cumulative HIV Cases by Gender (%), 2018

Figure 2-70: Oman - Cumulative HIV Cases by Age, 2018

Figure 2-71: GCC - Age Standardized Coronary Heart Disease Death Rate by Countries, 2017

Figure 2-72: GCC - CHD Related Deaths by Countries, 2017

Figure 2-73: GCC - CHD Related Deaths by Countries (%), 2017

Figure 2-74: GCC - Age Standardized Hypertension Death Rate by Countries, 2017

Figure 2-75: GCC - Hypertension Related Deaths by Countries, 2017

Figure 2-76: GCC - Hypertension Related Deaths by Countries (%), 2017

Figure 2-77: GCC - Age Standardized Stroke Death Rate by Countries, 2017

Figure 2-78: GCC - Stroke Related Deaths by Countries, 2017

Figure 2-79: GCC - Stroke Related Deaths by Countries (%), 2017

Figure 2-80: GCC - Obese Population by Countries (%), 2019

Figure 2-81: GCC - Body Mass Index by Countries, 2019

Figure 2-82: Saudi Arabia - Obesity Prevalence Rate (%), 2017 and 2022

Figure 2-83: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2017 and 2022

Figure 2-84: UAE - Prevalence Rate of Obesity and Overweight by Gender(%), 2016

Figure 2-85: UAE - Obese Adult Population (%), 2019

Figure 2-86: Kuwait - Prevalence Rate of Obesity and Overweight (%), 2016

Figure 2-87: Kuwait - Prevalence Rate of Obesity and Overweight by Gender (%), 2016

Figure 2-88: Bahrain - Prevalence Rate of Obesity and Overweight (%), 2016

Figure 2-89: Bahrain - Prevalence Rate of Obesity and Overweight by Gender (%), 2016

Figure 2-90: Qatar - Prevalence Rate of Obesity and Overweight (%), 2016

Figure 2-91: Qatar - Prevalence Rate of Obesity and Overweight by Gender (%), 2016

Figure 2-92: Oman - Obesity Prevalence Rate by Gender (%), 2016

Figure 2-93: GCC - Asthma Related Deaths by Countries, 2017

Figure 2-94: GCC - Asthma Related Deaths by Countries (%), 2017

Figure 2-95: GCC - Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017

Figure 2-96: GCC - Tuberculosis Related Deaths by Countries, 2017

Figure 2-97: GCC - Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017

Figure 2-98: GCC - Asthma Related Deaths by Countries (%), 2017

Figure 2-99: GCC - Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017

Figure 2-100: GCC - Influenza and Pneumonia Related Deaths by Countries, 2017

Figure 2-101: GCC - Influenza and Pneumonia Related Deaths by Countries (%), 2017

Figure 2-102: GCC - Age Standardized Influenza and Pneumonia Death Rate by Countries (per 100,000 People), 2017

Figure 2-103: GCC - COPD Prevalence Rate by Countries (%), 2018

Figure 2-104: GCC - COPD and Cystic Fibrosis Related Deaths by Countries, 2017

Figure 2-105: GCC - COPD and Cystic Fibrosis Related Deaths by Countries (%), 2017

Figure 2-106: GCC - Age Standardized COPD and Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017

Figure 2-107: GCC - Alzheimer/Dementia Related Deaths by Countries, 2017

Figure 2-108: GCC - Alzheimer/Dementia Related Deaths by Countries (%), 2017

Figure 2-109: GCC - Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017

Figure 3-1: GCC - Types of Drug Registration Process

Figure 3-2: Process Map for GCC Centralized Registration

Figure 3-3: GCC - Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2019

Figure 3-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2019

Figure 3-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Innovative/Biological Products (SAR/US$), 2019

Figure 3-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Generic Products (SAR/US$), 2019

Figure 3-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Intravenous Generic Products (SAR/US$), 2019

Figure 3-8: Saudi Arabia - Regulatory Process for Pharmaceuticals

Figure 3-9: Kuwait - Regulatory Process for Pharmaceuticals

Figure 3-10: UAE - Regulatory Process for Pharmaceuticals

Figure 3-11: Bahrain - Regulatory Process for Pharmaceuticals

Figure 3-12: Qatar - Regulatory Process for Pharmaceuticals

Figure 3-13: Oman - Regulatory Process for Pharmaceuticals

Figure 5-1: GCC - Pharmaceutical Market Size - Generic vs. Others (US$ Billion), 2018

Figure 5-2: GCC - Pharmaceutical Market Size - Generic vs. Others (%), 2018

Figure 5-3: GCC - Generic Drug Market Size (US$ Billion), 2018 - 2025

Figure 5-4: GCC - Patented and OTC Pharmaceutical Market Size (US$ Billion), 2018

Figure 5-5: GCC - Share of Patented Products in Pharmaceutical Market by Countries (%), 2016

Figure 5-6: GCC - Share of OTC Products in Pharmaceutical Market by Countries (%), 2016

Figure 5-7: GCC - Biosimilars Market Size (US$ Million), 2019 and 2025

Figure 5-8: GCC - Strategies Considered by New Biosimilars Manufacturers

Figure 5-9: Key Stakeholders for Launch of Biosimilars

Figure 6-1: Pharmaceutical Market Size - Saudi Arabia vs. Rest of GCC (%), 2018

Figure 6-2: Pharmaceutical Market Size - Saudi Arabia vs. Rest of MEA (%), 2018

Figure 6-3: Saudi Arabia - Pharmaceutical Market Size (US$ Billion), 2018 - 2025

Figure 6-4: Saudi Arabia - Pharmaceutical Market Share by Channel of Distribution (%), 2018

Figure 6-5: Saudi Arabia - Pharmaceutical Market Size by indication (%), 2018

Figure 6-6: Saudi Arabia - Number of New Product Launched by Indication, Q4 2018

Figure 6-7: Saudi Arabia - Sales Data of Leading Pharmaceutical Products (US$ Million), 2018

Figure 6-8: Saudi Arabia - Revenue of Leading Pharmaceutical Companies (US$ Million), Q4 2018

Figure 6-9: Saudi Arabia - Generic and Branded Pharmaceutical Market Size (%), 2018

Figure 6-10: Saudi Arabia - OTC and Prescribed Pharmaceuticals Market Size (US$ Billion), 2018

Figure 6-11: Saudi Arabia - OTC and Prescribed Pharmaceutical Market Size (%), 2018

Figure 7-1: Pharmaceutical Market Size - UAE vs. Rest of GCC (%), 2018

Figure 7-2: Pharmaceutical Market Size - UAE vs. Rest of MEA (%), 2018

Figure 7-3: UAE - Pharmaceutical Market Size by Channel of Distribution (%), 2018

Figure 7-4: UAE - Pharmaceutical Market Size (US$ Billion), 2018 - 2025

Figure 7-5: UAE - Pharmaceutical Export Market by Region (%), 2017

Figure 7-6: UAE - Pharmaceutical Export Market by Countries (%), 2017

Figure 7-7: UAE - Pharmaceutical Export Market by Products (%), 2018

Figure 7-8: UAE - Pharmaceutical Market Size by Therapeutic Indication (US$ Million), 2018

Figure 7-9: UAE - Number of New Launched Pharmaceutical Product by Indication, Q4 2018

Figure 7-10: UAE - Growth Rate of Leading Pharmaceutical Companies (%), 2018

Figure 7-11: UAE - Pharmaceutical Market Share by Type of Products (%), 2017

Figure 7-12: UAE - Pharmaceutical Market Share by Type of Products (%), 2018

Figure 7-13: UAE - Generic Drug Market Size (US$ Million), 2017 - 2025

Figure 8-1: Pharmaceutical Market Size - Kuwait vs. Rest of GCC (%), 2018

Figure 8-2: Pharmaceutical Market Size - Kuwait vs. Rest of MEA (%), 2018

Figure 8-3: Kuwait - Pharmaceutical Market Size (US$ Billion), 2018-2025

Figure 8-4: Kuwait - Pharmaceutical Market Size by Therapeutic Indication (%), 2018

Figure 8-5: Kuwait - Sales Data of Leading Pharmaceutical Products (US$ Million), Q4 2018

Figure 8-6: Kuwait - Pharmaceutical Market Size - MNC vs. Regional Companies (%), 2016

Figure 8-7: Kuwait - Julphar Pharmaceutical Share in Regional Pharmaceutical sales (%), 2016

Figure 8-8: Kuwait - Pharmaceutical Market Size by Leading Companies (US$ Million), Q4 2018

Figure 8-9: Kuwait - Generic Pharmaceutical Market Share (%), 2018 and 2025

Figure 8-10: Kuwait - Pharmaceutical Market by Type of Product (%), 2018

Figure 8-11: Kuwait - Generic Drug Market Share in Total market Size (%), 2018

Figure 8-12: Kuwait - OTC Pharmaceutical Market Share (%),2018 and 2025

Figure 9-1: Bahrain - Pharmaceutical Market Size - Bahrain vs. Rest of GCC (%), 2018

Figure 9-2: Bahrain - Pharmaceutical Market Size (US$ Million), 2018 - 2025

Figure 9-3: Bahrain - Pharmaceutical Market Size - Import vs. Total Market (US$ Million), 2018

Figure 9-4: Bahrain - Pharmaceutical market Share - Import vs. Other Market (%), 2018

Figure 9-5: Bahrain - Pharmaceutical market Share by Therapeutic Agents (%), 2018

Figure 9-6: Bahrain - Market Size by Leading Pharmaceutical Companies (US$ Million), Q4 2018

Figure 9-7: Bahrain - Share of Generics in Total Pharmaceutical Market (%)2018 and 2025

Figure 9-8: Bahrain - Share of OTC in Total Pharmaceutical Market (%) 2018 and 2025

Figure 9-9: Bahrain - Patented, Generics and OTC Pharmaceuticals Market Share (%), 2018

Figure 9-10: Bahrain - Patented, Generics and OTC Pharmaceuticals Market Share (%), 2025

Figure 9-11: Bahrain - Generic Pharmaceutical Market Size (US$ Million), 2018 and 2025

Figure 9-12: Bahrain - OTC Pharmaceutical Market Size (US$ Million), 2018 and 2025

Figure 10-1: Qatar - Pharmaceutical Market Size (US$ Million), 2015 - 2018

Figure 10-2: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of GCC (%), 2018

Figure 10-3: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of MEA (%), 2018

Figure 10-4: Qatar - Pharmaceutical Market Size (US$ Million), 2018 - 2025

Figure 10-5: Qatar - Pharmaceutical Market Size by Product Type (US$ Million), 2018

Figure 10-6: Qatar - Pharmaceutical Market Size by Product Type (%), 2018

Figure 10-7: Qatar - Pharmaceutical Market Size by Type of Product (US$ Million), 2025

Figure 11-1: Oman - Pharmaceutical Market Size (US$ Million), 2012, 2016 and 2018

Figure 11-2: Pharmaceutical Market Size - Oman vs. Rest of GCC (%), 2018

Figure 11-3: Pharmaceutical Market Size - Oman vs. Rest of MEA (%), 2018

Figure 11-4: Oman - Pharmaceutical Market Size (US$ million), 2019 - 2025

Figure 11-5: Oman - Import, Export and Other Pharmaceutical Market Size (US$ Million), 2018

Figure 11-6: Oman - Import, Export and Other Pharmaceutical Market Size (%), 2018

Figure 11-7: Oman - Share of Generics in Total Pharmaceutical Market (%) 2016, 2018 and 2025

Figure 11-8: Oman - Share of OTC in Total Pharmaceutical Market (%) 2016, 2018 and 2025

Figure 11-9: Oman - Patented, Generics and OTC Pharmaceuticals Market Share (%), 2018

Figure 11-10: Oman - Patented, Generics and OTC Pharmaceuticals Market Share (%), 2025

Figure 11-11: Oman - Generic Pharmaceutical Market Size (US$ Million), 2018 and 2025

Figure 11-12: Oman - OTC Pharmaceutical Market Size (US$ Million), 2018 and 2025

Figure 12-1: GCC - Pharmaceutical Import Market Size by Countries (US$ Billion), 2018

Figure 12-2: GCC - Pharmaceutical Import Market Size by Countries (%), 2018

Figure 12-3: GCC - Import Pharmaceutical Market Size (US$ Billion), 2016, 2017 and 2018

Figure 12-4: Saudi Arabia - Pharmaceutical Import Size (US$ Billion), 2016 - 2018

Figure 12-5: UAE - Pharmaceutical Import Size (US$ Billion), 2016 - 2018

Figure 12-6: Kuwait - Pharmaceutical Import Size (US$ Billion), 2016 - 2018

Figure 12-7: Bahrain - Pharmaceutical Import Size (US$ Million), 2016 - 2018

Figure 12-8: Qatar - Pharmaceutical Import Size (US$ Million), 2016 - 2018

Figure 12-9: Oman - Pharmaceutical Import Size (US$ Million), 2016 - 2018

Figure 12-10: GCC - Pharmaceutical Export Market Size by Countries (US$ Million), 2018

Figure 12-11: GCC - Pharmaceutical Export Market Size by Countries (%), 2018

Figure 12-12: GCC - Export Pharmaceutical Market Size (US$ Billion), 2016, 2017 and 2018

Figure 12-13: Saudi Arabia - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 12-14: UAE - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 12-15: Kuwait - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 12-16: Bahrain - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 12-17: Qatar - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 12-18: Oman - Pharmaceutical Export Size (US$ Million), 2016 - 2018

Figure 13-1: GCC - Number of Clinical Trials by Countries, 2019

Figure 13-2: GCC - Clinical Trials by Countries (%), 2019

Figure 13-3: GCC - Number of Clinical Trials by Status, 2019

Figure 13-4: GCC - Clinical Trials by Status (%), 2019

Figure 13-5: GCC - Number of Clinical Trial by Phase, 2019

Figure 13-6: GCC - Number of Clinical Trial by Phase (%), 2019

Figure 13-7: GCC - Numbers of Clinical Trials by Indications, 2019

Figure 13-8: GCC - Clinical Trials by Indications (%), 2019

Figure 13-9: GCC - Number of Cancer Related Clinical Trials by Countries, 2019

Figure 13-10: GCC - Cancer Related Clinical Trials by Countries (%), 2019

Figure 13-11: GCC - Number of Cancer Related Clinical Trials by Phase of Development, 2019

Figure 13-12: GCC - Number of Diabetes Related Clinical Trials by Countries, 2019

Figure 13-13: GCC - Diabetes Related Clinical Trials by Countries (%), 2019

Figure 13-14: GCC - Number of Diabetes Related Clinical Trials by Development Phase, 2019

Figure 13-15: GCC - Number of CVS Disorder Related Clinical Trials by Countries, 2019

Figure 13-16: GCC - CVS Disorder Related Clinical Trials by Countries (%), 2019

Figure 13-17: GCC - Number of CVS Disorders Related Clinical Trials by Development Phase, 2019

Figure 13-18: GCC - Number of Respiratory Disorder (Except Lung Cancer) Related Clinical trials by Countries, 2019

Figure 13-19: GCC - Respiratory Disorder (Except Lung Cancer) Related Clinical Trials by Countries (%), 2019

Figure 13-20: GCC - Number of Respiratory Disorders Related Clinical Trials by Development Phase, 2019

Figure 13-21: Saudi Arabia - Number of Clinical Trials by Development Phase, 2019

Figure 13-22: Saudi Arabia - Number of Clinical Trials by Status, 2019

Figure 13-23: Saudi Arabia - Numbers of Clinical Trials by Indications, 2019

Figure 13-24: Saudi Arabia - Clinical Trials by Indications (%), 2019

Figure 13-25: UAE - Clinical Trials in States of UAE (%), 2019

Figure 13-26: UAE - Number of Clinical Trials by Development Phase, 2019

Figure 13-27: UAE - Number of Clinical Trials by Status, 2019

Figure 13-28: UAE - Numbers of Clinical Trials by Indications, 2019

Figure 13-29: UAE - Clinical Trials by Indications (%), 2019

Figure 13-30: Kuwait - Number of Clinical Trials by Development Phase, 2019

Figure 13-31: Kuwait - Number of Clinical Trials by Status, 2019

Figure 13-32: Kuwait - Numbers of Clinical Trials by Indications, 2019

Figure 13-33: Kuwait - Clinical Trials by Indications (%), 2019

Figure 13-34: Bahrain - Number of Clinical Trials by Development Phase, 2019

Figure 13-35: Bahrain - Number of Clinical Trials by Status, 2019

Figure 13-36: Qatar - Number of Clinical Trials by Development Phase, 2019

Figure 13-37: Qatar - Number of Clinical Trials by Status, 2019

Figure 13-38: Qatar - Numbers of Clinical Trials by Indications, 2019

Figure 13-39: Kuwait - Clinical Trials by Indications (%), 2019

Figure 13-40: Oman - Number of Clinical Trials by Development Phase, 2019

Figure 13-41: Oman - Number of Clinical Trials by Status, 2019

Figure 14 1: Driving Factors for GCC Pharmaceutical Market

Figure 15-1: Challenges for GCC Pharmaceutical Market

Figure 16-1: GCC - Population Forecast by Countries (Million), 2025

Figure 16-2: GCC - Pharmaceutical Market Forecast by Countries (US$ Billion), 2025

Figure 16-3: GCC - Pharmaceutical Market Share Forecast by Countries (%), 2025

Figure 16-4: GCC - Cancer Drug Market Forecast (US$ Billion), 2018 and 2025

Figure 16-5: GCC - Generic Pharmaceutical Market Forecast (%), 2025

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Need custom market research solution? We can help you with that too.

About us

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.

Quick links

Contact us

104, First Floor A 8-9 Ansal Building,
Dr. Mukherjee Nagar,
Delhi-110009

7 Temasek Boulevard,
#12-07 Suntec Tower One,
Singapore 038987

info@Kuickresearch.com

+91-011-47067990,
+91-011-27650990

Stay Connected

Subscribe for updated News

© All Rights reserved, Kuick Research, 2022